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The purpose of the present work was to evaluate in vivo different antimicrobial therapies to eradicate 
osteomyelitis created in the femoral head of New Zealand rabbits. Five phosphate-based cements were 
evaluated: calcium phosphate cements (CPC) and calcium phosphate foams (CPF), both in their pristine 
form and loaded with doxycycline hyclate, and an intrinsic antimicrobial magnesium phosphate cement 
(MPC; not loaded with an antibiotic). The cements were implanted in a bone previously infected with 
Staphylococcus aureus to discern the effects of the type of antibiotic administration (systemic vs. local), 
porosity (microporosity, i.e. < 5 μm vs. macroporosity, i.e. > 5 μm) and type of antimicrobial 
mechanism (release of antibiotic vs. intrinsic antimicrobial activity) on the improvement of the health 
state of the infected animals. A new method was developed, with a more comprehensive composite 
score that integrates 5 parameters of bone infection, 4 parameters of bone structural integrity and 4 
parameters of bone regeneration. This method was used to evaluate the health state of the infected 
animals, both before and after osteomyelitis treatment. The results show that the composite score allows 
to discern statistically significant differences between treatments that individual evaluations were not 
able to identify. Despite none of the therapies completely eradicated the infection, it was observed that 
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macroporous materials (CPF and CPFd, the latter loaded with doxycycline hyclate) and intrinsic 
antimicrobial MPC allowed a better containment of the osteomyelitis. This study provides novel 
insights to understand the effect of different antimicrobial therapies in vivo, and a promising 
comprehensive methodology to evaluate the health state of the animals was developed. We expect that 
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 Antibiotic-loaded calcium phosphates cements were used for osteomyelitis treatment  
 Macroporous calcium phosphates showed better performance in vivo than microporous ones 
 Microporous magnesium phosphates cements had intrinsic antimicrobial activity in vivo 







Osteomyelitis, the infection of bone tissue or bone marrow by bacteria or fungi, can arise 
from the migration of a pathogen either present in the blood stream or in the bone through an 
open fracture or during a surgery1–3. Despite the improvement on prophylaxis, surgical 
techniques, postoperative care and availability of new antibiotics leading to superior treatment 
efficacies, perioperative osteomyelitis remains as one of the most serious complications in 
orthopaedics and traumatology4,5. In particular, surgical procedures involving open fractures, 
removal of bone tumours, joint replacement or treatment of a previous bone infection are 
susceptible to (re)infection. Among the different pathogens, Staphylococcus aureus (S. aureus) 
has been identified in 38% to 67% of the osteomyelitis cases diagnosed over the past decade6. 
Treatments against osteomyelitis traditionally consist in the systemic administration of 
antibiotics, which implies that only a small amount of the drug reaches the target site due to first 
pass effect, distribution, elimination, etc. In the case of osteomyelitis, the access of the antibiotic 
to the infection site is even more difficult due to the local destruction of blood vessels in the 
bone site. Moreover, it is well known that secondary effects can be associated to systemic drug 
administration. Substituting the systemic treatment with a local therapy may be a more efficient 
strategy, associating a lower dosage of the active principle and thus minimizing possible side 
effects7,8. 
The local treatment of osteomyelitis requires a carrier that releases the antimicrobial 
agent in a controlled manner. The most extended carrier currently used in clinics is poly(methyl 
methacrylate) (PMMA)9–11 which elute antibiotics slowly. Nonetheless, PMMA is non 
degradable (i.e. does not allow new bone formation) and requires a second surgery to remove it 
once the treatment is finished12,13. Therefore, the development of osteoconductive biomaterials 
that provide an adequate scaffold for new bone ingrowth and also have antimicrobial properties 
represents a milestone in the treatment of bone infections. Furthermore, injectable and 
biodegradable materials are preferable, as they can be implanted by minimally invasive surgery 
and avoid the second surgery needed to remove non-degradable implants11, thus minimizing the 
risk of (re)infection and reducing patient morbidity. 
Calcium phosphate cements (CPCs) are a large family of injectable pastes that are able to harden 
after being implanted in the body. After hardening, CPCs mimic the structure and composition of the 
mineral component of bone, providing them with excellent biocompatibility, bioactivity and 
osteoconductivity14. CPCs based on alpha tricalcium phosphate (α-TCP) have been used in minimally 
invasive surgery to regenerate bone defects, both as non-macroporous15 and as macroporous materials. 
Macroporous CPC, also called calcium phosphate foams (CPFs)16, count with  an interconnected 
network of pores larger than 5 µm (macropores) over the inherent microporous structure of CPCs 
(typically with sizes below 2 µm)17,18. Furthermore, CPCs and CPFs loaded with doxycycline hyclate 
have shown in vitro antimicrobial properties against Streptococcus sanguinis and Lactobacillus 
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salivarius in vitro19. Alternative injectable cements that recently have raised interest due to their 
intrinsic antimicrobial properties are magnesium phosphate cements (MPCs)20 . The active mechanisms 
of MPCs against bacteria have been ascribed to the alkaline pH and osmolar modifications of the local 
environment21. Despite the promising in vitro results of CPC, CPF and MPC to act as multifunctional 
biomaterials, their efficacy in vivo to simultaneously treat bone infection and their regenerative 
potential has not been studied yet. 
In order to evaluate the antimicrobial performance of a therapy, a generally accepted procedure 
consists on creating an osteomyelitis condition in an animal model and, after allowing a certain infection 
period, apply the therapeutic treatment22. Typically, the outcome of an in vivo osteomyelitis treatment 
has been quantified using the Smeltzer’s scale23. However, this scale is limited as it only evaluates the 
degree of bone destruction due to the infection and does not consider any signs of bone regeneration. 
To the best of authors’ knowledge, a scale evaluating simultaneously the severity of infection, bone 
structural integrity at the infection site and signs of bone remodelling to comprehensibly assess the 
osteomyelitis condition is not currently available. 
In this context, the aim of this work was two-fold. First, to assess the efficacy of antibiotic-loaded 
CPCs, CPFs and of intrinsically antibacterial MPC as therapies with the dual function of eradicating 
osteomyelitis and regenerating the affected bone tissue. This study was designed to understand the 
effects of material pore size, route of administration for antibiotic (local vs. systemic) and antimicrobial 
approach (local release of an antibiotic vs. material with intrinsic antimicrobial properties) on bone 
healing in a complex scenario of local bone infection. Second, to develop a novel multi-factorial 
evaluation to relate three different biological responses, i.e. extension of the infection, bone structural 
integrity and state of the bone regeneration process, in one global and comprehensive scale of the health 
state of the animal.  
 
2. Materials and methods 
2.1 Materials  
Three injectable bone grafts were tested along the study: CPCs, CPFs and MPC. CPCs and CPFs 
were both used in their pristine form and loaded with doxycycline hyclate (CPCd and CPFd, 
respectively). Therefore, a total of 5 different cements (CPC, CPCd, CPF, CPFd and MPC) were 
implanted. Table 1 provides an overview of the initial composition, product of the setting reaction, pore 





Table 1. Bone grafting materials used  
Bone 
graft 
Powder phase Liquid phase 









α-TCP + 2 wt% 
hydroxyapatite 
Distilled water 






hyclate (4 mg 
/kg) 19 
CPCd 
50 mg/mL of 
doxycycline hyclate 





α-TCP + 2 wt% 
hydroxyapatite 
1 wt% Polysorbate 
80 in distilled water  
CDHA  
Total = 66 
Macroporosity 













α-TCP + 2 wt% 




























α -TCP: α-Tricalcium Phosphate; CDHA: Calcium Deficient Hydroxyapatite; CPC: Calcium Phosphate Cement; 
CPF: Calcium Phosphate Foam; MPC: Magnesium Phosphate cement 
 
CPCs were prepared manually by mixing a powder phase with a liquid phase at a liquid to 
powder ratio of 0.55 mL/g19. The powder phase was α-Tricalcium Phosphate (α-TCP) with 2 wt% 
precipitated hydroxyapatite (ref. n. 7758-87-4 Merck). The liquid phase consisted either in distilled 
water for CPC or a 50 mg/mL aqueous solution of doxycycline hyclate (Sigma-Aldrich, doxycycline 
hydrochloride hemiethanolate hemihydrate, C22H24N2O8⋯HCl⋯0.5H2O⋯0.5C2H6O; MW: 1025.89 
g/mol, ref. n. D3000000) for CPCd. 
CPFs were prepared by simultaneously mixing and foaming the same powder phase as CPCs 
and an aqueous solution of 1 wt% Polysorbate 80 (ref. n. 59924 Sigma–Aldrich, UK) at a liquid to 
powder ratio of 0.55 mL/g. The mixing and foaming of the phases was performed simultaneously inside 
a 60 ml syringe using a custom-made mixer (stainless steel blade adapted to a Dremel 4000, Robert 
Bosch Tool Corporation) at 6000 rpm during 30 s17. To prepare the CPFd, doxycycline hyclate powder 
(amount equivalent to 50 mg/ml of liquid phase) was introduced in the syringe during foaming (at 
second 20) to allow its homogenization and foaming17. 
MPC was prepared mixing dead burnt magnesium oxide (MgO, ref. n. 1309-48-4, Merck) and 
sodium hydrogen phosphate (NaH2PO4, 7558-80-7, Fluka) at a 3.8:1 molar ratio and 3 wt% of borax 
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was added to retard the reaction (Fluka, ref. n. 72,000)20. The powder was manually mixed with distilled 
water at a liquid to powder ratio of 0.17 mL/g to prepare the cement paste.  
To guaranty the sterility for in vivo studies, the solid components were sterilized by gamma 
radiation at a 25 KGy dose and the liquid phases were sterilized by filtration through 0.22 µm 
membranes. After mixing the solid and liquid phase, all grafts had the consistency of a workable paste 
and were injected using sterile 5 mL syringes with 2 mm aperture. 
 
2.2. Development of osteomyelitis in in vivo model 
The in vivo study was performed at the animal experimentation facility of the Universidad de 
Santiago de Compostela, in Lugo, (Spain) with the ethical committee authorization: AE-LU-
002/2012/INV.MED.02/PAT[05]/AGC2. The use and handling of the animals was performed 
according to the European Union Guidelines for the Care and Use of Laboratory Animals (86/609/CE). 
In this study 42 adult female New Zealand rabbits (16 weeks old and average weight 5 kg) were used. 
All rabbits were quarantined three weeks prior to surgery. During the study, the animals were housed 
in separate cages in a climate-controlled room with free access to food and water. Before surgery, the 
rabbits were divided in randomized test groups of 6 rabbits each, as detailed in Figure 1.  
 
Figure 1. Design of the animal study including group nomenclature, sampling times and type of antimicrobial 
treatment, i.e. local (implantation of a material with antimicrobial activity) or systemic (oral administration of 
antibiotic in addition to the implantation of the material without antimicrobial activity). 
 
At day 0, the animals were anesthetized and the femoral condyle of one caudal leg, randomly 
selected, was exposed by a lateral longitudinal incision. A bone defect (∅ = 4 mm, length = 8 mm) was 
created parallel to the axis connecting the medial and lateral condyle in the distal part of the femur by 
trephination using constant saline irrigation to avoid thermal necrosis (Figure 2). Bacterial infection 
was induced with PMMA rods (∅ = 4 mm, length = 8 mm), which were previously immersed in a S. 
aureus inoculum for 16 h at 37 ºC, washed with phosphate buffer saline (PBS), dried, stored at -80 ºC 
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and used within a week. The rod was press-fit into the bone defect, the wound was cleaned thoroughly 
with povidone-iodine solution wipes (to prevent infection unrelated to the bone tissue) and sutured. 
Each animal received peri- and post-operative analgesia using buprenorphine (0.15 mg/Kg IM; Buprex, 
RB Pharmaceuticals, Berkshire, UK) and pain control with meloxicam (0.3 mg/Kg subcutaneous; 
Metacam, Boehringer Ingelheim, Barcelona, Spain). Each animal was monitored until full recovery 
from anaesthesia. No antibiotics were administrated to any rabbit before or after this first surgery. 
 
Figure 2. Sketch representing the defect performed in the rabbits’ femoral condyle 
 
At day 7, the animals in the Infection-7d group were euthanized for evaluation while the animals 
in all other groups were submitted to a second surgery. The second surgery consisted on removal of the 
PMMA rods, pus aspiration and placement of the corresponding bone graft (except for the Empty defect 
group) by injection (Figure 1). No surgical debridement was performed in any case. After filling the 
defect, the wound was sutured and all animals were treated with postoperative analgesia and pain 
control. The animals within the groups Empty defect, CPC and CPF further received a systemic daily 
doxycycline hyclate dose (4 mg/kg)24 dissolved in drinking water. Animals within the groups CPCd, 
CPFd and MPC did not receive systemic antibiotic since the implanted materials should have local 
antimicrobial activity. 
At day 28 all animals were euthanized. Both implanted and non-infected/non-implanted 
contralateral femurs were explanted and the surrounding soft tissues were removed. 
 
2.3 Systemic evaluation of the osteomyelitis state: blood test 
The systemic health state of the animals was evaluated through blood testing before surgery 
(day 0; n = 42), at 7 days after infection (Infection-7d group; n = 42) and at the end of the treatment 
period (day 28; n = 6). Blood tests were performed by Idexx Laboratories, Inc. (Barcelona, Spain) and 
the complete blood counts and plasma proteins were determined.  
The systemic markers evaluated from the blood test were divided into non-specific response 
(monocyte counts) and specific response (albumin/globulin ratio). A low albumin/globulin ratio 
indicated the presence of an infection in the animal, since acute inflammation triggers an increment in 
concentration and activity of lymphocytes, which produce immune proteins such as globulins to combat 
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the infection. The values of monocyte counts and albumin/globulin ratio were further normalized to a 
scale from 0 to 4 (according with Table 2) with the purpose to be included in the composite scale. 
 
2.4 Local evaluation of the osteomyelitis state 
2.4.1. Radiographic observation. The femoral condyle area was evaluated by X-ray images (Philips 
Super 80 CP). The bone density and degree of bone lesion around the implant (radiopacity) was scored 
by two independent experts using a scale from 0 to 4 according to Table 2. 
2.4.2. Histological analysis. After explanting and removing the soft tissues, the femurs were kept in 4 
v/v% formaldehyde solution for 3 weeks and afterwards cut (Exakt 300, Germany) normally to the axis 
of the cylindrical defect to obtain 2 mm circular slices of it. For each femur condyle, two cuts were 
stained using either Masson's trichrome staining (MT) or haematoxylin - eosin (HE) staining. The 
contralateral femur condyles were also processed for comparative purposes. 
Regarding sample preparation for MT staining, the samples were gradually dehydrated by 
progressive ethanol immersion. Afterwards, the ethanol was progressively replaced by PMMA resin 
(Tecnovit 7200 VLC, EXAKT, Germany). Samples were then UV-cured overnight (Exakt 520, 
Germany). The polymerized blocks were cut and polished (Exakt 400 CS, Exakt AW110, Germany) 
down to 30 - 70 µm slices. MT staining was then performed according common protocols.  
In contrast, for HE staining, the slices were decalcified using bone marrow biopsy decalcifying 
solution (05-M03005, Osteodec, Bio-Optica, Italy) during 3 months. Afterwards, the samples were 
embedded in paraffin, cut to an average thickness of 6 μm (RM2145 microtome, Leica, Germany), 
placed on a glass coverslips and stained with HE following standard protocols. 
2.4.3. Bone structural integrity evaluation. Stained samples were observed using a bright field optical 
microscope (AF 7000, Leica, Germany). Images of MT staining were segmented to separate red (fibrous 
tissue) from blue (bone/collagen) stained areas (Figure 3a). The zones of trabecular bone with collagen 
fiber alignment were observed with polarized light in MT stained samples (Figure 3b).  
In non-implanted contralateral femurs, the femur condyle was defined as the first region of 
interest (ROI-1), excluding the growth plate and the cortical part of the bone when visible. In implanted 
samples, the area surrounding the defect (equivalent to a ring of 0.8 mm of thickness measured from 




Figure 3. Representative examples of a) Masson's trichrome (MT) staining image of a bone condyle of a rabbit 
in the MPC group, b) polarized light image in MT staining (corresponding to a sample in Empty Defect group) 
showing in bright green (arrows) the zones of trabecular bone with collagen fiber alignment, and c) definition of 
the regions of interest (ROI-1 and ROI-2) for histomorphometric quantification; P1: perimeter of the 
biomaterial; P2: dilatation of the perimeter P1; A1: bone area delimited by the internal perimeter P1; A2: bone 
area delimited by the dilated perimeter P2 (P1, P2, A1 and A2 are the parameters used to calculate the trabecular 
bone pattern factor, TBPf, as indicated in Equation 1). 
 
For each region of interest the bone volume density (also called bone volume over total volume; 
BV/TV), the trabecular thickness (Tb.Th) and the trabecular bone pattern factor (TBPf) were evaluated 
using FiJi software25 and BoneJ plugin26, which are Java-based image processing programs developed 
at the National Institutes of Health and the Laboratory for Optical and Computational Instrumentation.  
BV/TV and Tb.Th were evaluated following the methodology described by Schindelin et al.26 
and Doube et al.25. To reduce variability in BV/TV and Tb.Th between animals, the values obtained for 
the implanted femur (ROI-2) were normalized by the respective value of the non-infected/non-
implanted contralateral femur (ROI-1) and the results were expressed as percentage of variation. The 
normalization transformed BV/TV and Tb.Th values to ∼ 0% if the implanted femur had similar 
properties than the contralateral femur (healthy bone) or negative values in case that the BV/TV and 
Tb.Th were reduced due to the infection process.  
The trabecular connectivity was evaluated measuring the TBPf according to indirect 
bidimensional methods27. Briefly, trabecular bone area (A1) and perimeter (P1) were measured 
delineating the edges of the implanted biomaterial. Using an automatic image analysis system, a 
concentric bigger circle was drawn, and trabecular bone area (A2) and perimeter (P2) were measured 
again (Figure 3c). TBPf is defined as a quotient of the difference of the first and the second 
measurement27:  
TBPf = (P1–P2)/(A1–A2)  Equation 1 
In the bigger circle, bone area always increases without regard of the curvature. However, bone 
perimeter only increases in convex surfaces. Trabecular bone with many concave structures (healthy) 
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shows a negative TBPf. In contrast, many convex structures (osteopenia/osteoporosis) produces a 
positive value27.  
To integrate these parameters in the overall score, the BV/TV, Tb.Th and TBPf values were 
normalized to a scale from 0 to 4 (according with Table 2).  
2.4.4. Bone regenerative process and bone infection evaluation. The collagen orientation in new, 
growing bone was observed with MT stained samples under polarized light (Figure 3b). Brighter areas 
showed oriented collagen fibers. In addition, the inflammatory infiltrate, bone sequestrum, 
revascularization, active bone cells and organization of the fibrous tissue were evaluated with HE 
images acquired randomly in four different frames of each femoral condyle sample. These semi-
quantitative evaluations were performed by two independent experts using a scale from 0 to 4 according 




Table 2. Description and scoring criteria of the semi-quantitative parameters evaluated to determine the degree 
of bone infection, bone structural integrity and regenerative process in scale from 0 to 4. 





Monocyte density determined 
by blood test 
0 : maximum monocyte density 
4: minimum monocyte density 
Albumin/globulin 
(A/G) ratio 
Plasma protein concentration 
determined by blood test 
0: minimum A/G ratio  
4: maximum A/G ratio 
Inflammatory 
infiltrate 
Frequency of monocytes in HE 
staining 
0: monocytes observed in the four images  
4: no monocytes observed in any of the four images 
Fibrosis 
Amount of fibrotic tissue in 
HE staining 
0: fibrotic tissue observed in the four images 
4: no fibrotic tissue observed in any of the four 
images 
Bone sequestrum 
Bone trabeculae isolated by 
inflammatory infiltrate in HE 
staining 
0: sequestrum observed in the four images 





Bone density  Radiographic evaluation of 
bone lesion 
0: severe sequestrum formation and/or bone 
destruction  
4: no signs of sequestrum or bone destruction  
Bone volume density 
(BV/TV) 
Bone volume over total 
volume in MT staining 
0: minimum BV/TV (negative values) 
4: maximum BV/TV (∼ 0 or positive values) 
Trabecular thickness 
(Tb.Th)  
Thickness of the trabecular 
bone in MT staining 
0: minimum Tb.Th (negative values) 
4: maximum Tb.Th (∼ 0 or positive values) 
Trabecular bone 
pattern factor (TBPf) 
Connectivity of the trabecular 
bone in MT staining 
0: maximum TBPf (positive values) 
4: minimum TBPf (negative values) 
Bone 
regeneration 
Revascularization Presence of blood vessels in 
HE staining 
0: absence of blood vessels in the four images 
4: presence of blood vessels in the four images 
Cellular activity 
Presence of osteoblasts, 
osteocytes and/or osteoclasts 
in HE staining 
0: absence of bone cells in the four images 
4: presence of bone cells in the four images 
Organization of 
fibrous tissue 
Alignment of the fibers in the 
inflammatory infiltrate in HE 
staining 
0: no signals of alignment in any of the four images 
4: fibers oriented in a preferential direction in the 
four images 
Collagen orientation 
in new growing bone 
Alignment of collagen fibers 
observed in MT staining under 
polarized light 
0: no signals of alignment in any of the four images 






2.5 Evaluation of the efficacy of the treatment 
An extensive evaluation of the health state of the animals using a composite score was 
performed, considering three different categories: 1) infection, 2) bone structural integrity and 3) 
regenerative processes (Figure 4). The value of each category was scored between 0 and 4 as described 
below, using the parameters evaluated according with Table 2. 
2.5.1 Infection score. Calculated as average of systemic (monocyte counts and albumin/globulin ratio 
evaluated by blood test) and local (inflammatory infiltrate, fibrosis and presence of sequestrum 
evaluated by HE staining) parameters. The score was normalized to a 0 to 4 scale, being 0 severe signs 
of infection and 4 no signs of infection (Table 2).  
2.5.2 Bone structural integrity score. Calculated as the average of the three histomorphometric 
parameters evaluated from MT staining (BV/TV, Tb.Th and TBPf) and the bone density evaluated 
radiographically. The numerical values were all normalized to a 0 to 4 scale, 4 indicating high structural 
integrity (Table 2). 
2.5.3 Regenerative processes score. Calculated as the average of the following four histomorphometric 
parameters: revascularization, presence of active bone cells, organization in fibrous tissue and collagen 
orientation in new growing bone. A scale between 0 and 4 was used, 4 indicating signs of important 
and active regenerative actions (Table 2). 
2.5.4 Calculation of the health state composite score. The composite score, which indicated the overall 
health state of animals, was calculated using Equation 2. 
 
Health State Composite Score = Infection score + Bone structural integrity score + Regenerative process 
score    (Equation 2) 
 
Therefore the composite health score ranges from 0 (poor health state as consequence of the 




Figure 4. Schematic representation of the three categories considered to calculate the animal health state 
composite score according to Equation 2. Each category includes the parameters evaluated to calculate its value 
and the meaning of the minimum and maximum scores. Each parameter or category was scored between 0 and 4 
according to Table 2. 
 
2.6. Statistical analysis 
Data was statistically analysed by applying one-factor ANOVA test. In the case of composite 
scores, a maximum of 2 outliers were removed before applying one-factor ANOVA test. Significant 
differences between groups were determined by Tukey analysis. Statistical significance was considered 
when p < 0.05 and data are presented as mean ± standard deviation. Statistical analysis was performed 
using Minitab 16 software (Minitab, Inc., USA). 
 
3. Results 
All animals survived the entire assay, being sacrificed at 7 or 28 days as planned. All animals 
presented an antalgic posture of the operated limb and a reduction of food intake. Two rabbits out of 
six of the Empty defect group presented ataxia and diarrhoea. 
 
3.1. Systemic evaluation of the osteomyelitis state 
Blood testing was performed before surgery (day 0), 7 days after infection (day 7) and after the 
bone grafting treatments (day 28). Figure 5a and 5b shows the monocyte counts and albumin/globulin 
ratio (A/G ratio), respectively. A statistically significant increase in monocyte counts was observed 
between Healthy group (day 0) and Infection-7d group, along with a statistically significant decrease in 
the A/G ratio. In contrast, the monocyte counts and the A/G ratio did not significantly change over time 





Figure 5. Summary of blood test results: a) Monocyte density and b) albumin/globulin ratio (values not yet 
normalized). Same letters indicate no statistically significant differences between groups (p > 0.05). 
 
3.2. Local evaluation of bone infection and bone regenerative process 
Figure 6 shows representative HE staining images that exemplify the phenomena used to score 
the bone infection and the bone regenerative process.  
 
Figure 6. Representative Haematoxylin-Eosin stained optical microscope images of different samples implanted 
in the femoral condyle of rabbits showing: a) encapsulation of a trabecula and b) alignment of the fibers in the 
inflammatory infiltrate (Empty defect sample; upper left image); c) monocytes in the inflammatory infiltrate, d) 
osteocytes and e) osteoclastic (Howship’s) lacuna (CPC sample, upper right image); f) active osteoclast and g) 
osteoblasts (CPF sample; lower left);  h) one blood vessel and i) active osteoblasts (CPFd sample; lower right). 
 
Figure 7 summarizes the result of both bone infection and regenerative process categories, 
which were scored in a 0 to 4 scale (see Table 2). A value of 0 indicates no signals of infection or of 
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regenerative process, whereas a value of 4 indicates high signals of infection or of regenerative process 
(see Figure 4). 
 
 
Figure 7. Scores of the parameters categorized: a) local bone infection (inflammatory infiltrate, fibrosis and 
sequestrum), and b) regenerative process (revascularization, bone cells activity, orientation of fibrous tissue and 
collagen orientation in bone tissue). The parameters were evaluated on Haematoxylin-Eosin staining images in 
accordance with Table 2. A value of 0 (centre of the graph) indicates high infection/ no signs of regenerative 
process, while a value of 4 (periphery of the graph) indicates no signs of infection/high signs of regenerative 
process. Error bars and significant statistical differences between groups were not included for clarity of the 
results. 
 
The results from the bone infection category are described below. Infection-7d showed the 
highest values of fibrosis (i.e. amount of fibrotic tissue) and bone sequestrum (i.e. a bone trabecula 
isolated by inflammatory cells). This indicates that 7 days after infection the animals were under a 
severe osteomyelitis. Unexpectedly, low signs of inflammatory infiltrate (i.e. amount of monocytes) 
were observed for the Infection-7d and the Empty group. Fibrosis was observed in all groups to a similar 
extent (no statistically significant differences). Infection-7d and MPC groups showed statistically 
significant higher signals of bone sequestrum than Empty and CPCd groups. The non-infected/non-
implanted contralateral femur did not show signs of bone infection along the entire experiment (data 
not shown). 
The results from the bone regenerative process category are described below. Revascularization 
and collagen orientation were the least frequently observed signals of bone regeneration in the 
osteomyelitis site. Most groups presented values equal or below 1.5 for these two parameters and only 
the CPF group showed higher signals of revascularization with a score equal to 3 (significantly different 
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to Infection-7d and CPCd groups). The orientation of fibrous tissue within the new growing bone did 
not show differences between groups. Surprisingly, the orientation of fibrous tissue and bone cell 
activity were maximum for Infection-7d group. After 28 days, although systemic or local treatments 
were applied, both orientation of collagen and bone cell activity were reduced indicating a lower degree 
of bone regeneration.  
 
3.3. Local evaluation of bone structural integrity 
The trabecular volume (BV/TV) variation and the Trabecular Thickness (Tb.Th) variation are 
summarized in Figure 8a and b, respectively. The variation in each parameter at the ROI-2 was 
calculated against the ROI-1 of the non-infected/non-implanted contralateral femur. Therefore, a similar 
degree of BV/TV and Tb.Th in the implanted bone compared to the contralateral femur would give a 
variation value close to 0%. Negative values indicate a decrement of the parameter in the implanted 
area (ROI-2) respect to the contralateral femur (ROI-1).  
The Infection-7d group presented a median value of BV/TV variation around -20 % with an 
important dispersion (Figure 8a). The decrease in trabecular volume in the infected/implanted femurs, 
which was rather heterogeneous between animals, could be associated with local osteomyelitis. After 
the treatment, the Empty, CPCd and CPF groups showed the most negative BV/TV median values 
(around -60 %), indicating more local bone destruction. In contrast, CPFd and MPC groups kept BV/TV 
median values similar to Infection-7d group, indicating the arrest of bone destruction, and were the only 
groups that presented statistical significant differences with CPCd group, which showed the lowest 
BV/TV value. 
The decrease in trabecular thickness (Tb.Th variation, Figure 8b) was smaller for the Empty, 
CPF, CPFd and MPC groups (Tb.Th between -10 and -20 %) than for Infection-7d, CPC and CPCd 
groups (Tb.Th between -40 and -60 %). This indicates that Infection-7d, CPC and CPCd groups had 
the most significant decrease in trabecular thickness, which can be ascribed to a more severe 
osteomyelitis process. This decrease in trabecular thickness was however only statistically significantly 
different for the CPCd group respect to Empty, CPF, CPFd and MPC groups. 
The decrease of trabecular thickness was more important than the decrement of trabecular 
volume for half of the groups (Infection-7d, CPC and CPCd), whereas a similar percentage was obtained 
for the other groups. 
Similar results were observed for the trabecular bone pattern factor (TBPf) variation (Figure 
8c). On the one hand, the Empty, CPF and CPFd groups showed positive TBPf median values, 
indicating a loss of trabecular connectivity. On the other hand, the Infection-7d, CPC, CPCd and MPC 
groups showed negative TBPf median values, revealing a healthy trabecular connectivity. No 
significant differences were observed between treatments. 
The results of bone density (Figure 8d) by radiographic analysis according to Table 2 did not 
show any sign of bone mass loss (normal bone density considered as 4) for the Infection-7d group. At 
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28 days, all treatment groups showed significant reduction of bone density respect Infection-7d group. 
Most groups showed a bone density around 2, except CPC group showing the lowest bone density. 
 
Figure 8. Histomorphometry results including a) bone volume density (BV/TV) variation and b) trabecular 
thickness (Tb.Th) variation between ROI-2 (implanted femur) and ROI-1 (non-infected/non-implanted 
contralateral femur, c) trabecular bone pattern factor (TBPf) representing the connectivity of the trabeculae in 
ROI-2, and d) radiographic semi-quantification of bone density (0 representing low and 4 representing normal 
bone mass). For BV/TV and Tb.Th a value close to zero indicates high trabecular volume and high trabecular 
thickness, respectively. For TBPf, a negative value indicates a healthy architecture of the trabeculae. For bone 
density, a higher number indicates a higher bone density. Same letters indicate no statistical differences between 
groups (p > 0.05). 
 
3.4. Global outcome of the efficacy of the treatments against osteomyelitis 
The results of systemic infection (Figure 5, non-normalized data), local infection and 
regenerative process (Figure 7, normalized data within 0-4 scale), and bone structure (Figure 8, non-
normalized data) were pulled together to create Figure 9, which shows the scores obtained for each 
category (infection, bone structural integrity and regenerative process) as well as the health state 
composite score. The value for each category was calculated as the average of the parameters included 
according to Table 2 and Figure 4. The most relevant differences between groups within categories are 
indicated below. None of the treatments showed any statistical significant differences regarding the 
category infection. Regarding bone structural integrity, the best results were shown for Infection-7d and 
MPC groups, whereas Empty, CPC and CPCd groups showed the worst outcome. Regarding the bone 
regeneration process, best results were shown for CPF, CPFd and MPC groups, whereas Infection-7d, 
Empty, CPC and CPCd groups showed the poorest bone regeneration.  
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The three categories independently evaluated were added up according to Equation 2 to get an 
overall and comprehensive evaluation of the efficacy of the treatments to eradicate osteomyelitis. A low 
value of the composite score indicates a severe osteomyelitis. Infection-7d group showed the worst 
health state (with a value of 4.7 out of 12). This score confirmed the presence of severe osteomyelitis 
after the infection period. After 28 days of treatment, the Empty, CPC and CPCd groups showed a very 
similar composite score (between 4.2 and 4.7) than the Infection-7d group. In contrast, CPF, CPFd and 
MPC groups presented a statistically significant higher composite score (between 6.1 and 6.4), showing 
signs of improvement of the health state. 
 
Figure 9. Scores for the categories evaluated separately (infection, bone structural integrity and regenerative 
process) and the health state composite score quantified following Equation 2. Regarding the infection score, a 
low value indicates high bone infection, whereas a high value indicates low bone infection. For bone structural 
integrity and regenerative process, a low value indicates a poor bone structural integrity/regenerative process, 
whereas a high value indicates a high bone structural integrity/regenerative process. For the health state 
composite score, a high value indicates a good health of the animal, whereas a low value indicates a poor health 
state. Statistics are indicated by minuscule letters (infection), majuscule letters (bone structural integrity), 
number (regeneration) and composite score (symbol). Same letters, numbers or symbols indicate no statistical 
differences between groups within the correspondent score (p > 0.05). 
 
4. Discussion 
A surgical procedure always involves a prophylaxis treatment to reduce the risk of infection, 
including a systemic perioperative therapy with antibiotics. Despite such precautions, osteomyelitis still 
represents around 1 % of the outcome of an orthopaedic surgery28,29. The management of bone 
infections is one of the current challenges for healthcare systems. The type of treatment that must be 
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employed to eradicate the osteomyelitis depends on the stage of bone infection, the individual and the 
specific pathogen30. The treatment usually involves a surgical procedure, with a debridement phase, in 
addition to the systemic and local antimicrobial therapy. 
In the present work, an animal model for the creation and treatment of osteomyelitis was 
employed based on previous works1,31. The model consisted in causing a perioperative infection by 
placing a temporal implant coated with sessile bacteria in a femoral head defect of New Zealand rabbits. 
After 7 days of infection, the temporal implants used to generate osteomyelitis were replaced by 
antimicrobial, injectable and osteoconductive materials aiming to heal osteomyelitis. Surgical 
debridement and removal of the infected tissue were not performed, only pus was aspired. The infection 
created was extensive, so the biomaterials faced a challenging scenario. 
Osteomyelitis perturbs local homeostasis, triggering a cascade of inflammatory response and 
wound healing. Initially, an acute inflammation causes an increase of inflammatory cells (monocytes 
and neutrophils) in the systemic circulation, which reach the infected site. On site, monocytes 
differentiate into macrophages, which together with neutrophils release oxidative species and cytokines. 
Cytokines are chemical messengers that recruit even more inflammatory cells to fight the infection and 
endothelial cells to quickly synthesize fibrous tissue at the infection site. Macrophages also phagocytize 
dead cells and tissue/material debris. If the acute inflammation does not fade away, the cellular events 
change after few days, the condition being then named chronic inflammation. Prolonged inflammation 
is detrimental for the affected site, since high level of oxidation damages healthy cells and tissue, while 
at the same time bone remodelling processes are hindered32. In an ideal scenario, a local and/or systemic 
treatment together with the immune system can overcome the osteomyelitis. After this period, 
inflammatory cells migrate back and the tissue recovers its physiological balance. In the case of 
osteomyelitis in New Zealand rabbits, the amount of systemic monocytes should decrease after ~ 28 
days31, if the treatment applied is effective enough compared to the extent of the infection. Once the 
normality of the tissue is restored, several more weeks are needed to be able to observe the results of 
bone remodelling, which synthesizes new bone with the adequate trabecular architecture and irrigated 
with blood vessels created by angiogenesis33.  
The severity of osteomyelitis may be defined by systemic and/or local evaluations4. Its clinic 
diagnostic is commonly limited to the least invasive methods available, i.e. radiography and blood tests. 
An approach to evaluate bone osteomyelitis in a rabbit model was previously proposed by Smeltzer et 
al.23. The main limitation of Smeltzer’s evaluation is that it only evaluates bone destruction parameters. 
The present work provides a more comprehensive composite score to determine variations in the health 
state of the animals caused by the osteomyelitis and the therapies used to eradicate it. This new 
composite score considers three different categories: bone infection, bone structural integrity and bone 
regeneration (Figure 4). The present study shows that the proposed composite score allows the 
assessment of statistically significant differences between antimicrobial therapies, which the individual 
parameters were not able to discern.  
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The Infection-7d group showed clear signs of systemic infection (high count of monocytes and 
low counts of albumin/globulin ratio) (Figure 5) and of local infection (high sequestrum) (Figure 7a). 
However, the inflammatory infiltrate observed was low (Figure 7a), the fibrous tissue was oriented and 
bone cell activity was observed (Figure 7b). In addition to that, a slightly negative BV/TV (-10 %) and 
a negative TBPf (-2.5 mm) (Figure 8a and c) was determined, indicating that the bone volume and 
thickness had been only slightly affected, respectively. In accordance to that, the bone density observed 
by radiographies did not show signs of infection at 7 days (Figure 8d). This could indicate that at 7 days 
the bone properties were still not affected by the osteomyelitis process. With time, the analysed 
parameters showed that the therapies applied were successful to arrest bone infection and improve bone 
regeneration. However, none of the treatments were effective to significantly enhance bone structural 
integrity by slowing or stopping the deterioration of the trabecular volume and thickness with time 
(Figure 9). This evidences that one of the limitations of this study is that the evaluation was only done 
at two time points (7 and 28 days), thus missing the time course evolution of the infection. It can be 
speculated that a longer evaluation time would have been crucial to detect an improvement of the bone 
structure. Evaluating only two time points was decided for ethical reasons, to reduce the number of 
animals. 
While MPC presents intrinsic antimicrobial activity21, CPC and CPF require the incorporation 
of an antimicrobial agent, in this case doxycycline hyclate, to present antimicrobial character17. 
Therefore, the animal study was designed to evaluate the effectiveness of different treatments to 
eradicate the bone infection focusing on 1) the method of antibiotic administration (systemic for Empty 
defect, CPC and CPF groups vs. local for CPCd and CPFd), 2) the type of antimicrobial agent (local 
release of doxycycline hyclate for CPCd and CPFd vs. intrinsic antimicrobial MPC) and 3) the porosity 
of the local antimicrobial carrier. In general, the global evaluation of osteomyelitis showed that 
macroporous CDHA (CPF and CPFd) and microporous MPC allowed a better containment of the 
osteomyelitis condition (Figure 9). Nonetheless, none of the treatments evaluated completely eradicated 
the induced bone infection. This was ascribed to the severity and extension of the infection created, 
which extended to the surrounding soft tissues instead of being limited to a local bone area, as 
previously observed in similar models34,35. 
 
4.1. The method of antibiotic administration (local vs. systemic) 
The health state composite score (Figure 9) does not show significant statistical differences 
between the methods of antibiotic administration (CPC vs CPCd and CPF vs CPFd). This means that 
under the conditions of this study, the local and systemic administration of doxycycline hyclate were 
equally effective to counteract the infection. Therefore, despite the short half-life of doxycycline hyclate 
(less than 2 days at 37 °C36), it could be speculated that the carriers (both CPCd and CPFd) protected 
the antibiotic from degradation and its antimicrobial activity was kept at a similar level than the daily 
renewal of systemic antibiotic administration.  
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A previous work showed that CPF specimens loaded with 50 mg of doxycycline hyclate (same 
amount as in the current work) released around 1 mg of doxycycline hyclate after 100h17. This amount 
that would be released locally at the infection site was only 20 times lower than the typical systemic 
dose used in rabbits (20 mg for a 5 kg rabbit), where the drug gets distributed along the body and has 
to overcome several body barriers to reach the infected site.  
Nevertheless, it should be considered that the region of action of the local administrated 
antibiotic is limited to the surroundings of the implant, making the bone defect susceptible to reinfection 
if the local concentration of antibiotic decreases below its therapeutic window. Therefore, for optimal 
screening of antimicrobial therapies, a more controlled method to produce the bone infection without 
spreading to other tissues is still required. 
 
4.2. The type of local antimicrobial agent (release of doxycycline hyclate vs. intrinsic antimicrobial 
activity of MPCs) 
CPCs and MPCs have similar intrinsic porosity in the range of 0.006-0.1 mm for CPCs19 and 
0.006-70 mm for MPCs20 (Table 1). Therefore, the effectiveness of the type of local antimicrobial agent 
was tested comparing CPCd and MPC groups. The health state composite score (Figure 9) shows that 
the intrinsic antimicrobial properties of MPC were more effective to improve the health state of the 
animals than the doxycycline hyclate released by CPCd. In previous works, CPCs loaded with 
doxycycline hyclate released relatively low amounts of drug, about 5 % in 4 days19. This low release is 
ascribed to the low accessibility of fluids to the bulk of the material due to the small size of the pores, 
hampering its diffusion. Therein, in our work the release of low amounts of antibiotic is expected from 
CPCs locally, explaining its lower efficiency with respect to MPC.  
To the best of the author’s knowledge, MPC demonstrated for the first time in vivo its intrinsic 
antimicrobial properties. The antimicrobial action of MPC was attributed to the local increase of pH 
(0.85 g/ml of MPC in PBS caused pH ∼ 11) and the high osmolarity of the environment (0.85 g/ml of 
MPC in PBS caused ∼ 700 mOs/Kg after 72h)21. This antimicrobial activity, together with good 
biocompatibility and biodegradability37,38, make MPC a promising material for bone grafting and 
prophylaxis against bone infections. 
 
4.3. The porosity of the local antimicrobial carrier (microporous i.e. CPC vs. macroporous i.e. CPF) 
CPCs have intrinsic microporosity with pores smaller than 2 μm19, whereas CPFs present a 
superimposed network of interconnected macropores (bigger than 5 µm) over the CPCs’ intrinsic 
porosity17 (Table 1). The importance of the porosity was revealed by the composite score (Figure 9), 
which shows that the health state of the animals was better when they were treated with macroporous 
materials (CPF and CPFd) than with only microporous materials (CPC and CPCd). The better 
performance of doxycycline hyclate-loaded macroporous CDHA (CPFd) in comparison with the 
doxycycline hyclate-loaded microporous CDHA (CPCd) can be easily linked to the higher release of 
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doxycycline hyclate (up to 13 times more)17. The higher dose of antibiotic could substantially decrease 
the infection and therefore explain the better activity in the osteomyelitic animals evaluated.  
The better performance of pristine macroporous CDHA (CPF; antibiotic provided systemically) 
compared to the pristine microporous CDHA (CPC) can be assigned to their ability to preserve the bone 
structure integrity (i.e. healthy trabecular architecture) and enhance bone regeneration39. This can be 
ascribed to the better fluid exchange in the macroporous materials, allowing immune cells to penetrate 
into the scaffold and therefore increase their chances to contend the infection. Specifically, CPFs 
showed double scoring in bone regeneration than the empty defect or only microporous CPCs. This 
result correlated well with previous works in which CPFs were implanted in the femur condyle of New 
Zealand rabbits and good osteoconductive properties were observed, the CPFs being gradually replaced 
by bone while CPCs were not degraded18,40,41. Therefore, it can be concluded that macroporosity in CPF 
allows for better fluid exchange, which promotes bone cells activity, vascularization and better 
distribution of the antibiotic (either systemically or locally administrated) that synergistically 
counterbalance the destruction of bone. 
In comparison with biodegradable polymeric carriers of antibiotics7, the biodegradable 
materials tested in this study have the advantage to be injectable, bioactive and osteoconductive. 
Therefore, these materials offer the possibility to be implanted via minimally invasive surgery and can 
promote the growing of new bone in parallel to the resorption of the implant, leading to the regeneration 
of bone tissue42. In comparison with other biodegradable and injectable inorganic cements used as 
antimicrobial carriers i.e. gypsum43, the resorption rate of calcium phosphates better matches the bone 
regeneration rate42, turning them into a better alternative. 
 
5. Conclusions 
The multifactorial score proposed in this work provides an extended evaluation of the health 
state of the animals, considering factors grouped in three different categories, i.e. bone infection, bone 
structural integrity and bone regeneration. These categories are not considered in traditional 
osteomyelitis evaluation scores. The new composite scale developed in this work allows to discern 
statistically significant differences between antimicrobial therapies used to eradicate osteomyelitis state 
of the animals, which the individual categories were not enable to discern. It is therefore useful to 
evaluate in vivo the efficacy of biomaterials for bone regeneration with local antibiotic releasing 
properties. Under the present study conditions, local or systemic administration of doxycycline hyclate 
showed equivalent antimicrobial performance. Macroporosity in bioceramics was confirmed to be a key 
parameter, as macroporous materials (with pores larger than 5 µm) showed better performance than 
microporous materials (with pores smaller than 5 µm). MPC (which does not contain drug itself) 
confirmed its intrinsic antimicrobial activity in vivo, showing similar performance than macroporous 
materials loaded with doxycycline hyclate (CPFd). The injectability and osteoconductivity, together 
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with either the intrinsic antimicrobial activity of MPC or the possibility to use CPF as carrier for an 
antibiotic active principle, confirm these materials as promising candidates for minimal invasive bone 
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